Brexafemme

Chemical Nameibrexafungerp
Dosage FormTablets (oral; 150 mg)
Drug ClassAntifungals
SystemFemale reproductive
CompanySCYNEXIS Inc.
Approval Year2021

Indication

  • For the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC).
Last updated on 11/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Brexafemme (ibrexafungerp tablets) Prescribing Information2021SCYNEXIS Inc., Jersey City, NJ